Concepedia

Author

John H. Kehne

Yale University

Also Known As

J H KEHNE, J H Kehne, J Kehne, J. H. KEHNE, J. H. Kehne, J.H. Kehne, JOHN H. KEHNE, Jochen Kehne, John H Kehne, John H. Kehne

83

Publications

3.9K

Citations

34

H-Index

72

Concepts

All Affiliations

Yale UniversityConnecticut Mental Health CenterHormel (United States)University of UtahThe Ohio State University at Marion
JH

About

John H. Kehne is an author at Yale University specializing in medicine, neuroscience, and neuropharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

23

36

2K

2

Social Sciences

15

17

929

3

Health Sciences

11

11

547

4

Natural Sciences

1

1

74

5

Anesthesia

1

1

21

John H. Kehne

×

51

Publications

3.3K

Citations

30

H-Index

YearCitations

Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.

John H. Kehne, B M Baron, A A Carr,

Journal of Pharmacology and Experimental Therapeutics

1996

358

Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.

S.M. Sorensen, John H. Kehne, Gina M. Fadayel,

Journal of Pharmacology and Experimental Therapeutics

1993

256

Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine

Michael D. Lesem, Tram Tran-Johnson, Robert Riesenberg,

The British Journal of Psychiatry

2011

153

Effects of the Selective 5-HT2A Receptor Antagonist MDL 100,907 on MDMA-Induced Locomotor Stimulation in Rats

John H. Kehne

Neuropsychopharmacology

1996

133

NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations

John H. Kehne, Timothy C. McCloskey, Bruce M. Baron,

European Journal of Pharmacology

1991

127

Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function

Michael G. Palfreyman, Christopher J. Schmidt, Stephen M. Sorensen,

Psychopharmacology

1993

125

Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo‐controlled clinical trial with inhaled loxapine

Joseph A. Kwentus, Robert Riesenberg, Morteza Marandi,

Bipolar Disorders

2012

124

Habituation and Sensitization of Startle Reflexes Elicited Electrically from the Brainstem

Michael T. Davis, Thomas Parisi, David S. Gendelman,

Science

1982

123

Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP)

Brian D. Klein, Catherine Jacobson, Cameron S. Metcalf,

Neurochemical Research

2017

122

5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats

Robert Padich, Timothy C. McCloskey, John H. Kehne

Psychopharmacology

1996

120

Page 1